Upadacitinib manufacturers and suppliers in india

Upadacitinib

CAS:: 1310726-60-3

MF:: C17H19F3N6O

MW:: 380.37

Suppliers by country/region

Company Type

Properties

Density: 1.56±0.1 g/cm3(Predicted)

storage temp.: Store at -20°C

solubility: DMSO:42.67(Max Conc. mg/mL);112.17(Max Conc. mM)
DMSO:PBS (pH 7.2) (1:1):0.5(Max Conc. mg/mL);1.31(Max Conc. mM)
DMF:30.0(Max Conc. mg/mL);78.87(Max Conc. mM)
Ethanol:76.0(Max Conc. mg/mL);199.8(Max Conc. mM)

form: A crystalline solid

pka: 11.89±0.60(Predicted)

color: White to off-white

InChI: InChI=1S/C17H19F3N6O/c1-2-10-7-25(16(27)24-9-17(18,19)20)8-11(10)13-5-22-14-6-23-15-12(26(13)14)3-4-21-15/h3-6,10-11,21H,2,7-9H2,1H3,(H,24,27)/t10-,11+/m1/s1

InChIKey: WYQFJHHDOKWSHR-MNOVXSKESA-N

SMILES: N1(C(NCC(F)(F)F)=O)C[C@H](C2N3C4C=CNC=4N=CC3=NC=2)[C@H](CC)C1

Safety Information

Symbol(GHS): GHS07

Signal word: Warning

Hazard statements: H302

Precautionary statements: P280-P305+P351+P338

Use

Upadacitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adults who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (DMARDs). Upadacitinib may be used as monotherapy or in combination with methotrexate.